Pub Date : 1999-10-10DOI: 10.5649/JJPHCS1975.25.502
Takanori Miura, R. Kojima, Kazumasa Negita, Akio Katsumi, M. Ota, Masayo Yamasita, T. Kubota, M. Mizutani, F. Takatsu, Yoshio Suzuki
The aim of this study was to compare iopamidol 370 mg I/mL with iomeprol 400 mg I/mL, regarding the incidence of immediate and delayed adverse reactions to the contrast media in patients receiving such drugs for coronary angiography. A total of 4298 patinets participated in the study consisting of 2203 and 2093 patients in the iopamidol and iomeprol groups, respectively. The incidence of adverse reactions was determined by assessing the number of patients with immediate adverse reactions (up to 60 min after drug administration) and delayed adverse reactions (within 14 days after under goin angiography). The immediate adverse reactions were monitored during and after the completion of drug administration, and delayed adverse reactions were surveyed by questionnaire over the telephone. There was no significant difference in the incidence of immediate adverse reactions between both drug groups: 6.4% for iopamidol vs. 6.3% for iomeprol. On the other hand, the incidence of delayed adverse reactions in the iomeprol-treated group (7.3%) was significantly less than that in iopamidol-treated group (9.1%). The incidence of delayed adverse reactions of patients with renal dysfunction (Serum creatine 1.5 mg/dL) in the iomeprol-treated group (41.3%) was also lower than that in the iopamidol-treated group (55.2%). These results showed no obvious difference in the incidence of immediate adverse reactions between the two groups, while the incidence of delayed adverse reactions was lower in the iomeprol-treated group, thus suggesting that the usage of iomeprol with a low osmolality was more useful in protecting patients with renal dysfunction from adverse reactions induced by contrast media.
{"title":"The Incidence of Immediate and Delayed Adverse Reactions to Contrast Media Caused by Coronary Angiography Examination : A Comparison between Iopamidol and Iomeprol","authors":"Takanori Miura, R. Kojima, Kazumasa Negita, Akio Katsumi, M. Ota, Masayo Yamasita, T. Kubota, M. Mizutani, F. Takatsu, Yoshio Suzuki","doi":"10.5649/JJPHCS1975.25.502","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.25.502","url":null,"abstract":"The aim of this study was to compare iopamidol 370 mg I/mL with iomeprol 400 mg I/mL, regarding the incidence of immediate and delayed adverse reactions to the contrast media in patients receiving such drugs for coronary angiography. A total of 4298 patinets participated in the study consisting of 2203 and 2093 patients in the iopamidol and iomeprol groups, respectively. The incidence of adverse reactions was determined by assessing the number of patients with immediate adverse reactions (up to 60 min after drug administration) and delayed adverse reactions (within 14 days after under goin angiography). The immediate adverse reactions were monitored during and after the completion of drug administration, and delayed adverse reactions were surveyed by questionnaire over the telephone. There was no significant difference in the incidence of immediate adverse reactions between both drug groups: 6.4% for iopamidol vs. 6.3% for iomeprol. On the other hand, the incidence of delayed adverse reactions in the iomeprol-treated group (7.3%) was significantly less than that in iopamidol-treated group (9.1%). The incidence of delayed adverse reactions of patients with renal dysfunction (Serum creatine 1.5 mg/dL) in the iomeprol-treated group (41.3%) was also lower than that in the iopamidol-treated group (55.2%). These results showed no obvious difference in the incidence of immediate adverse reactions between the two groups, while the incidence of delayed adverse reactions was lower in the iomeprol-treated group, thus suggesting that the usage of iomeprol with a low osmolality was more useful in protecting patients with renal dysfunction from adverse reactions induced by contrast media.","PeriodicalId":17399,"journal":{"name":"Journal of the Nippon Hospital Pharmacists Association","volume":"169 1","pages":"502-510"},"PeriodicalIF":0.0,"publicationDate":"1999-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89023258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-08-10DOI: 10.5649/JJPHCS1975.25.407
T. Asakura, H. Seino, M. Mizuno, S. Nozaki, R. Abe
{"title":"A Study on Insulin Vial Coring","authors":"T. Asakura, H. Seino, M. Mizuno, S. Nozaki, R. Abe","doi":"10.5649/JJPHCS1975.25.407","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.25.407","url":null,"abstract":"","PeriodicalId":17399,"journal":{"name":"Journal of the Nippon Hospital Pharmacists Association","volume":"99 1","pages":"407-413"},"PeriodicalIF":0.0,"publicationDate":"1999-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91516093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-04-10DOI: 10.5649/JJPHCS1975.25.118
修徳 郡, 文雄 板垣, 博範 長坂, 吏志 岸野, 健 井関, 邦彦 小林, 勝巳 宮崎
Hyperammonemia which is caused by inherited urea cycle enzyme deficiencies, is often fatal when acute symptoms of hyperammonemic coma (vomiting, unconsciousnessf convulsion, respiratory paralysis, et al.) appear and continue without any medical treatment. L-Arginine or sodium benzoate has been used for the treatment of hyperammonemia. However, it is difficult for children to take such reagents orally in powder form due to the bulky dose volume and their offensive bitter taste. A significant decrease in medication compliance has thus led to hyperammonemic coma or liver transplantation.In this study, we prepared tablets containing a high percentage of L-arginine or sodium benzoate by the wetgranulation method, and administered them to several children with hyperammonemia. Remarkable improvements in the compliance and clinical effects, as well as decreases in the occurance of comas and the serum ammonium levels, have been observed in all patients.
{"title":"先天性尿素サイクル異常症に伴う高アンモニア血症治療薬L-アルギニン, 安息香酸ナトリウムの錠剤化とその臨床応用","authors":"修徳 郡, 文雄 板垣, 博範 長坂, 吏志 岸野, 健 井関, 邦彦 小林, 勝巳 宮崎","doi":"10.5649/JJPHCS1975.25.118","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.25.118","url":null,"abstract":"Hyperammonemia which is caused by inherited urea cycle enzyme deficiencies, is often fatal when acute symptoms of hyperammonemic coma (vomiting, unconsciousnessf convulsion, respiratory paralysis, et al.) appear and continue without any medical treatment. L-Arginine or sodium benzoate has been used for the treatment of hyperammonemia. However, it is difficult for children to take such reagents orally in powder form due to the bulky dose volume and their offensive bitter taste. A significant decrease in medication compliance has thus led to hyperammonemic coma or liver transplantation.In this study, we prepared tablets containing a high percentage of L-arginine or sodium benzoate by the wetgranulation method, and administered them to several children with hyperammonemia. Remarkable improvements in the compliance and clinical effects, as well as decreases in the occurance of comas and the serum ammonium levels, have been observed in all patients.","PeriodicalId":17399,"journal":{"name":"Journal of the Nippon Hospital Pharmacists Association","volume":"21 1","pages":"118-122"},"PeriodicalIF":0.0,"publicationDate":"1999-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76202899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-02-10DOI: 10.5649/JJPHCS1975.25.88
T. Sugiyama, T. Shibayama, Yasuyuki Takano, Takuji Arima, Y. Katagiri
{"title":"Development of Prescription Checking System : Sub System in Dispensing Support System","authors":"T. Sugiyama, T. Shibayama, Yasuyuki Takano, Takuji Arima, Y. Katagiri","doi":"10.5649/JJPHCS1975.25.88","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.25.88","url":null,"abstract":"","PeriodicalId":17399,"journal":{"name":"Journal of the Nippon Hospital Pharmacists Association","volume":"22 1","pages":"88-97"},"PeriodicalIF":0.0,"publicationDate":"1999-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72687602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-02-10DOI: 10.5649/JJPHCS1975.25.82
Kazunori Shiotsu, N. Tanoue, Kazumi Nakamura, Miho Kubota, S. Tsuruta, K. Arimori, M. Nakano
{"title":"Studies on the Stability of Polymyxin B Sulfate Solutions and on Their Shelf-lives.","authors":"Kazunori Shiotsu, N. Tanoue, Kazumi Nakamura, Miho Kubota, S. Tsuruta, K. Arimori, M. Nakano","doi":"10.5649/JJPHCS1975.25.82","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.25.82","url":null,"abstract":"","PeriodicalId":17399,"journal":{"name":"Journal of the Nippon Hospital Pharmacists Association","volume":"57 1","pages":"82-87"},"PeriodicalIF":0.0,"publicationDate":"1999-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76228652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-01-01DOI: 10.5649/jjphcs1975.25.131
M. Iwata, Yuri Takahashi, H. Takeuchi, E. Kawahara, K. Takayama, Shoichi Shirotake
Operating conditions affecting the dissolution characteristics of glibenclamide were investigated with the flow-through-cell method (the third method of dissolution test in JP XIII). The partition coefficient of glibenclamide between octanol and phosphate buffer (pH 7.4) was observed to be 24.2, thus suggesting the lipophilic nature of glibenclamide. The flow indicator on the apparatus in the flow-through-cell method did not reflect the real flow rate of the dissolution media.The dissolution-time curve (ADT) value increased in line with the decrease in the bead's diameter when the flow rate of the indicator was slow (8 ml/min). On the other hand, the ADT value was hardly affected by the bead's diameter when the flow rate was fast (24 ml/min), however, a wide deviation in the ADT values was seen during such conditions. The operating condition of flow rate and bead's diameter was optimized based on the response surface method. As a result, a flow rate of 14 ml/min and a bead diameter of 0.5 mm were estimated as the optimal conditions to obtain the largest ADT and the smallest deviation in the ADT. When using the fl ow-through-cell method, the operating condition should be optimized based on the nature of pharmaceuticals under test.
{"title":"Dissolution Profiles of Glibenclamide Tablet Using Flow-Through-Cell Method","authors":"M. Iwata, Yuri Takahashi, H. Takeuchi, E. Kawahara, K. Takayama, Shoichi Shirotake","doi":"10.5649/jjphcs1975.25.131","DOIUrl":"https://doi.org/10.5649/jjphcs1975.25.131","url":null,"abstract":"Operating conditions affecting the dissolution characteristics of glibenclamide were investigated with the flow-through-cell method (the third method of dissolution test in JP XIII). The partition coefficient of glibenclamide between octanol and phosphate buffer (pH 7.4) was observed to be 24.2, thus suggesting the lipophilic nature of glibenclamide. The flow indicator on the apparatus in the flow-through-cell method did not reflect the real flow rate of the dissolution media.The dissolution-time curve (ADT) value increased in line with the decrease in the bead's diameter when the flow rate of the indicator was slow (8 ml/min). On the other hand, the ADT value was hardly affected by the bead's diameter when the flow rate was fast (24 ml/min), however, a wide deviation in the ADT values was seen during such conditions. The operating condition of flow rate and bead's diameter was optimized based on the response surface method. As a result, a flow rate of 14 ml/min and a bead diameter of 0.5 mm were estimated as the optimal conditions to obtain the largest ADT and the smallest deviation in the ADT. When using the fl ow-through-cell method, the operating condition should be optimized based on the nature of pharmaceuticals under test.","PeriodicalId":17399,"journal":{"name":"Journal of the Nippon Hospital Pharmacists Association","volume":"8 1","pages":"131-137"},"PeriodicalIF":0.0,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86674246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1998-12-10DOI: 10.5649/JJPHCS1975.24.677
Yoko Shiojiri, Y. Kurosaki, H. Kawasaki, Kazue Yanagisawa, H. Araki, Y. Gomita, Megumi Oda, Y. Takeda, Yoshio Hiraki
Improving the patient's QOL is an important matter for guaranteeing proper pharmacotherapy. Lugol's solution (LS, iodine content: I2 3.4%, KI 6.6%) for internal use is a useful drug for the inhibition of radioiodine uptake to the thyroid gland. However, it is difficult for patients, especially children to take this agent or ally due to its unpleasant taste, terrible smell, and peculiar color. The present study was conducted to improve both the taste and the smell of LS, by using soft drinks containing ascorbic acid. Iodine (I2) molecules in LS are reduced to iodide (F) by ascorbic acid, and the peculiar color of LS thus vanished. The amount of L (+)-ascorbic acid (VC) required to remove the color was in good agreement with the rational value. The improvement in the taste, smell, stimulation on the tongue, and the overall ease in taking the following four LS preparations, i.e., the control LS (LS-I), added by Simple Syrup solution (LS-II), by VC solution (LS-III), and by POCARISWEAT® (LS-IV), were then evaluated in the ten healthy adult volunteers. LS-II, -III and -IV, significantly improved all the elements compared with LSI, and eight volunteers selected LS-IV as the easiest preparation. The inhibitory effect of LS-IV to the radioiodine uptake to the thyroid gland was also confirmed in a patient with neuroblastoma based on a clinical diagnosis using 131I-metaiodobenzyl-guanidine scintigraphy. These results suggest that the medication method for taking LS with soft drinks containing VC improves the compliance and QOL of these patients.
{"title":"Medication Instructions for Improving the QOL : Lugol's Solution for Internal Use via Soft Drinks Containing Ascorbic Acid","authors":"Yoko Shiojiri, Y. Kurosaki, H. Kawasaki, Kazue Yanagisawa, H. Araki, Y. Gomita, Megumi Oda, Y. Takeda, Yoshio Hiraki","doi":"10.5649/JJPHCS1975.24.677","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.24.677","url":null,"abstract":"Improving the patient's QOL is an important matter for guaranteeing proper pharmacotherapy. Lugol's solution (LS, iodine content: I2 3.4%, KI 6.6%) for internal use is a useful drug for the inhibition of radioiodine uptake to the thyroid gland. However, it is difficult for patients, especially children to take this agent or ally due to its unpleasant taste, terrible smell, and peculiar color. The present study was conducted to improve both the taste and the smell of LS, by using soft drinks containing ascorbic acid. Iodine (I2) molecules in LS are reduced to iodide (F) by ascorbic acid, and the peculiar color of LS thus vanished. The amount of L (+)-ascorbic acid (VC) required to remove the color was in good agreement with the rational value. The improvement in the taste, smell, stimulation on the tongue, and the overall ease in taking the following four LS preparations, i.e., the control LS (LS-I), added by Simple Syrup solution (LS-II), by VC solution (LS-III), and by POCARISWEAT® (LS-IV), were then evaluated in the ten healthy adult volunteers. LS-II, -III and -IV, significantly improved all the elements compared with LSI, and eight volunteers selected LS-IV as the easiest preparation. The inhibitory effect of LS-IV to the radioiodine uptake to the thyroid gland was also confirmed in a patient with neuroblastoma based on a clinical diagnosis using 131I-metaiodobenzyl-guanidine scintigraphy. These results suggest that the medication method for taking LS with soft drinks containing VC improves the compliance and QOL of these patients.","PeriodicalId":17399,"journal":{"name":"Journal of the Nippon Hospital Pharmacists Association","volume":"50 1","pages":"677-682"},"PeriodicalIF":0.0,"publicationDate":"1998-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88718983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1998-12-10DOI: 10.5649/JJPHCS1975.24.750
Kazuo Samizo, M. Horiguchi, T. Yoshimura, Y. Yamazaki, N. Nishimura, C. Ishikura, T. Tamura, Masao Itoh
{"title":"Compatibility Test of ALFAROL^ Powder with Other Powders and Granules","authors":"Kazuo Samizo, M. Horiguchi, T. Yoshimura, Y. Yamazaki, N. Nishimura, C. Ishikura, T. Tamura, Masao Itoh","doi":"10.5649/JJPHCS1975.24.750","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.24.750","url":null,"abstract":"","PeriodicalId":17399,"journal":{"name":"Journal of the Nippon Hospital Pharmacists Association","volume":"54 1","pages":"750-758"},"PeriodicalIF":0.0,"publicationDate":"1998-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86388503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1998-12-10DOI: 10.5649/JJPHCS1975.24.687
N. Hoshino, N. Shibata, T. Minouchi, A. Yamaji
A sodium gualenate gargle (Az-G) for the treatment of pharyngitis, tonsilitis, stomatitis and oral wound was prepared by using various thickening agents carboxymethylcellulose sodium (CMCNa), sodium polyacrylate (PANa) and sodium alginate (AGNa), and the effect of such thickening agents on the release-profiles of sodium gualenate (Az) from Az-G were evaluated both in vitro and in vivo. The mean dissolution time in vitro (MDTin vitro) of Az from preparations with 1.0% or more CMCNa and 2.0% AGNa were significantly higher than that of the control preparation (without thickening agent). However, the preparation with 0.2% PANa did not increase the MDTin vitro significantly despite the fact that the preparation had a higher viscosity than the control preparation. In the application of Az-G to healthy volunteers, the amount of Az adhering to the oral mucosa increased significantly in proportion to the concentration of CMCNa. On the other hand, MDTin vivo increased significantly at 1.0% of CMCNa, though it did not increase significantly at 2.0%. There was no significant rise in the amount of Az adhered on oral mucosa and MDTin vivo in the preparations with PANa and AGNa. The highest values regarding the amount of Az adhering to the oral mucosa, MDTin vivo and the amount of Az released in saliva obtained at 30-33 min after application were observed in the preparation with 1.0% CMCNa. These results suggest CMCNa to be the most excellent thickening agent for the preparation of Az-G and the optimum content was 1.0%.
{"title":"Evaluation of Thickening Agents in Preparation of Sodium Gualenate Gargles.","authors":"N. Hoshino, N. Shibata, T. Minouchi, A. Yamaji","doi":"10.5649/JJPHCS1975.24.687","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.24.687","url":null,"abstract":"A sodium gualenate gargle (Az-G) for the treatment of pharyngitis, tonsilitis, stomatitis and oral wound was prepared by using various thickening agents carboxymethylcellulose sodium (CMCNa), sodium polyacrylate (PANa) and sodium alginate (AGNa), and the effect of such thickening agents on the release-profiles of sodium gualenate (Az) from Az-G were evaluated both in vitro and in vivo. The mean dissolution time in vitro (MDTin vitro) of Az from preparations with 1.0% or more CMCNa and 2.0% AGNa were significantly higher than that of the control preparation (without thickening agent). However, the preparation with 0.2% PANa did not increase the MDTin vitro significantly despite the fact that the preparation had a higher viscosity than the control preparation. In the application of Az-G to healthy volunteers, the amount of Az adhering to the oral mucosa increased significantly in proportion to the concentration of CMCNa. On the other hand, MDTin vivo increased significantly at 1.0% of CMCNa, though it did not increase significantly at 2.0%. There was no significant rise in the amount of Az adhered on oral mucosa and MDTin vivo in the preparations with PANa and AGNa. The highest values regarding the amount of Az adhering to the oral mucosa, MDTin vivo and the amount of Az released in saliva obtained at 30-33 min after application were observed in the preparation with 1.0% CMCNa. These results suggest CMCNa to be the most excellent thickening agent for the preparation of Az-G and the optimum content was 1.0%.","PeriodicalId":17399,"journal":{"name":"Journal of the Nippon Hospital Pharmacists Association","volume":"51 1","pages":"687-696"},"PeriodicalIF":0.0,"publicationDate":"1998-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88513769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：